Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Breast Cancer Metastatic × Fulvestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 93 Neoplasms 12 Neoplasm Metastasis 12 Hereditary Sensory and Autonomic Neuropathies 3 Advanced Breast Cancer 3 Recurrence 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Multiple Endocrine Neoplasia Type 1 2 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms, Male 2 Solid Malignancies 1 Recurrent Uterine Corpus Carcinoma 1 Neoplasms by Site 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Lethal Congenital Contracture Syndrome 2 1 Hyperglycemia 1 Hormone Receptor Positive HER-2 Negative Breast Cancer 1 Hormone Receptor Positive Breast Cancer 1 HER2-positive Breast Cancer 1 Exanthema 1 Estrogen Receptor-positive Breast Cancer 1 Carcinoma, Ovarian Epithelial 1 Breast Diseases 1 Breast Cancer Metastatic 1 Anatomic Stage IV Breast Cancer AJCC v8 1 Advanced Metastatic Breast Cancer 1 Advanced Cancer 1

Interventions

tusamitamab ravtansine 1 nirogacestat 1 exemestane 1 Tamoxifen 1 Letrozole 1 Gemcitabine 1 Fulvestrant 1 Docetaxel 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04059484 2026-02-24

AMEERA-3

Sanofi

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡